

KMZ Rosenman Docker No.: 330310.00100
Customer No. 27160

U.S. Patent Application No.
10/427,929

DECLARATION

As the below named inventor, I hereby declare that:

My residence, post office and citizenship is as stated below next to my name,

I believe I am the original, first and sole inventor of the subject matter claimed and for which a patent is sought on the invention entitled INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE INDUCED CLINICAL CONDITIONS, the specification of which was filed as U.S. Patent Application No. 10/427,929 on May 2, 2003, and was amended on May 2, 2003.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

<u>Prior Foreign Application(s):</u>	<u>Priority Claimed</u>			
<u>Number</u>	<u>Country</u>	<u>Day/Month/Year filed</u>	<u>Yes</u>	<u>No</u>

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

<u>Prior Provisional Application(s):</u>	<u>Filing Date</u>
<u>Application Number</u>	

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of

KMZ Rosenman Docket No.: 330310.00100
Customer No. 27160

U.S. Patent Application No.
10/427,929

Title 35, United States Code, Section 112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U. S. Application(s):

Serial No.

Filing Date Status: Patented, Pending, Abandoned

The undersigned hereby grant(s) the firm of KATTEN MUCHIN ZAVIS ROSENMAN the power to insert on this Declaration any further identification, including the application number and filing date, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.
All future correspondence should be addressed to:

27160
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, IL. 60661
Tel.: 202.625.3500

Full name of original first and sole inventor: Leland Shapiro

Inventor's signature: Leland Shapiro

Date: 8/24/93

Residence: c/o University of Colorado Health Science Center, Division of
Infectious Diseases, Campus Box B168, 4200 E. Ninth
Avenue, Denver, CO 80262

Citizenship: United States

Post Office Address: Same as above